Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2009;11(3):115.
doi: 10.1186/ar2724. Epub 2009 Jun 22.

Predicting the future of anti-tumor necrosis factor therapy

Cornelis L Verweij
Editorial

Predicting the future of anti-tumor necrosis factor therapy

Cornelis L Verweij. Arthritis Res Ther. 2009.

Abstract

Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients, reflecting that there are 'responders' as well as 'nonresponders'. Given the destructive nature of RA, the risk of adverse effects, and considerable costs for therapy, there is a strong need to make predictions on success before the start of therapy. In the current issue of Arthritis Research & Therapy, Hueber and colleagues become the first to present a multi-parameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment. Ultimately, this finding may contribute to a personalized form of medicine, whereby a specific therapy will be applied that is best suited to an individual patient.

PubMed Disclaimer

Comment on

References

    1. Hueber W, Tomooka BH, Batliwalla F, Li Wetian, Monach PA, Tibshirani R, Van Vollenhove RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH. Blood autoantibody and cytokine profiles predict response to anti-TNF therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R76. doi: 10.1186/ar2706. - DOI - PMC - PubMed
    1. Batliwalla F, Li W, Bienkowska J, Damle A, Khalili H, Hueber W, Allaire M, Mcrann M, Robinson W, Kern M, Carulli JP, Gregersen PK. Differential peripheral blood gene expression profile of rheumatoid arthritis in response to anti-TNF treatment [abstract] Arthritis Rheum. 2007;56:S700. doi: 10.1002/art.22412. - DOI
    1. van Baarsen EGM, Wijbrandts CA, Rustenburg F, Pouw Kraan TCTM van der, Dijkmans BAC, Tak PP, Verweij CL. Pharmacogenomics of anti-TNF treatment in rheumatoid arthritis reveals an active baseline TNF response profile in all patients [abstract] Arthritis Rheum. 2008;58:S776.
    1. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ. Molecular discrimination of responders and non-responders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther. 2008;10:R50. - PMC - PubMed
    1. van Baarsen EGM, Wijbrandts CA, Rustenburg F, Cantaert T, Pouw Kraan TC van der, Baeten D, Dijkmans B, Tak PP, Verweij CL. IFN/TNF cross-regulation in vivo during infliximab treatment in rheumatoid arthritis [abstract] Arthritis Rheum. 2008;58:S670.

MeSH terms

Substances

LinkOut - more resources